Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy

MT Newswires Live03-24

Ocugen (OCGN) said Tuesday that its experimental gene therapy showed a 31% reduction in lesion growth compared with a control group in a phase 2 clinical trial for a dry age-related macular degeneration treatment.

The 12-month results evaluating the medium dose of the candidate showed a 27% slower rate of structural loss among patients with geographic atrophy, the company said.

The treatment maintained a safety profile with no serious adverse events or related complications reported during the study, Ocugen said.

The company also said it expects to start a phase 3 registrational trial for the therapy in Q3.

Shares of the company were down by more than 10% in Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621502062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621502062","market":"sh","top_or_hot":-1,"title":"Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN) said Tuesday that its experimental gene therapy showed a 31% reduction in lesion growth compared with a control group in a phase 2 clinical trial for a dry age-related macular degeneration treatment.</p><p>The 12-month results evaluating the medium dose of the candidate showed a 27% slower rate of structural loss among patients with geographic atrophy, the company said.</p><p>The treatment maintained a safety profile with no serious adverse events or related complications reported during the study, Ocugen said.</p><p>The company also said it expects to start a phase 3 registrational trial for the therapy in Q3.</p><p>Shares of the company were down by more than 10% in Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-24 20:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> (OCGN) said Tuesday that its experimental gene therapy showed a 31% reduction in lesion growth compared with a control group in a phase 2 clinical trial for a dry age-related macular degeneration treatment.</p><p>The 12-month results evaluating the medium dose of the candidate showed a 27% slower rate of structural loss among patients with geographic atrophy, the company said.</p><p>The treatment maintained a safety profile with no serious adverse events or related complications reported during the study, Ocugen said.</p><p>The company also said it expects to start a phase 3 registrational trial for the therapy in Q3.</p><p>Shares of the company were down by more than 10% in Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621502062","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621502062","pubTimestamp":1774355353,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ocugen  said Tuesday that its experimental gene therapy showed a 31% reduction in lesion growth compared with a control group in a phase 2 clinical trial for a dry age-related macular degeneration treatment.The 12-month results evaluating the medium dose of the candidate showed a 27% slower rate of structural loss among patients with geographic atrophy, the company said.The treatment maintained a safety profile with no serious adverse events or related complications reported during the study, Ocugen said.The company also said it expects to start a phase 3 registrational trial for the therapy in Q3.Shares of the company were down by more than 10% in Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4139":"生物科技","BK4563":"昨日强势股","OCGN":"Ocugen"},"translate_title":"Ocugen报告眼病治疗2期试验数据积极","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":1.5},"content_text":"Ocugen (OCGN) said Tuesday that its experimental gene therapy showed a 31% reduction in lesion growth compared with a control group in a phase 2 clinical trial for a dry age-related macular degeneration treatment.The 12-month results evaluating the medium dose of the candidate showed a 27% slower rate of structural loss among patients with geographic atrophy, the company said.The treatment maintained a safety profile with no serious adverse events or related complications reported during the study, Ocugen said.The company also said it expects to start a phase 3 registrational trial for the therapy in Q3.Shares of the company were down by more than 10% in Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621502062","isCrawlerRequest":true}